CD44 was instead outlined as a biomarker of prognosis of posterior fossa ependymomas as well as being in association with abnormal activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway (PI3K-Akt pathway) [15]. This evidence concerns the gene AKT1 and posterior fossa ependymoma.